出品｜虎嗅科技组 作者｜宋思杭 编辑｜苗正卿 头图｜视觉中国 虎嗅从多个独立信源获悉，半年前，某DeepSeek核心高管已悄然离职创业，并将于2025年圣诞节前后 发布Agent产品。有信源告诉虎嗅，该高管系原DeepSeek CTO。不过另有知情人士向虎嗅透露， DeepSeek内部并无明确的CTO一职，即在DeepSeek内部并无明确为"CTO"的职位，但有承担相应工作的 人士。 上述知情人士向虎嗅进一步透露，这位DeepSeek核心高管的创业项目已拿到IDG资本融资。对此，虎嗅 向IDG方面求证，IDG相关人士表示对此事并不知情。有业内人士向虎嗅表示，通常情况下这种"不予置 评"的态度在投资圈并不罕见，尤其是涉及高敏感度的人才流动和前沿技术赛道时。 将时间倒推半年前，2024年12月至2025年1月正是DeepSeek最热的时期，彼时DeepSeek前后分别发布并 开源了具有极致降本增效能力的V3模型和推理模型R1.而该核心高管却选择在此时离职创业并切入 Agent赛道，这一时间点的选择耐人寻味。 由此产生的几个疑问是：这位核心高管究竟为何选择在DeepSeek最热的时期推出？如果要做Agent，为 何 ...

Group 1 - The core viewpoint is that China's new productive forces are emerging on the global stage, presenting unlimited investment potential, with the venture capital industry playing a crucial role in this process [1] - DeepSeek's advancements in AI, including the release of its flagship model V3 and reasoning model R1, demonstrate China's rapid progress in AI capabilities, now comparable to global leaders like OpenAI, with costs significantly lower at one-thirtieth [1] - The rise of Chinese AI startups, as highlighted by the mention of DeepSeek and others, indicates that China's AI capabilities have entered the world's top tier, with a narrowing gap of only two to three months behind global standards [1] Group 2 - The biopharmaceutical sector in China is experiencing a similar transformation, with 30% of global big pharma's license-in activities coming from Chinese biotech startups in 2024, up from 0% in 2019, marking a shift from being a major recipient to a leading source of licenses [2] - China's export structure has significantly changed over the past 20 years, with machinery, electrical equipment, and consumer electronics now accounting for 42% of total exports, indicating a strong global competitiveness in new energy vehicles [2] - Numerous Chinese tech companies, both large and small, are expanding their international presence, showcasing their competitive strength and potential to develop into world-class enterprises [2] Group 3 - Venture capital is closely linked to technological development, characterized by high-risk tolerance and a long-term value focus, supporting innovation and participating in the growth of companies [3] - Despite challenges in recent years, the global venture capital landscape shows that six out of seven companies founded after 2010 and valued over $100 billion are from China, highlighting significant investment opportunities [3] - Key investment areas identified include artificial intelligence, biopharmaceuticals, renewable energy, and robotics, with AI expected to create substantial opportunities starting in 2025 [3]

Group 1 - The core theme of the 2025 Global Investor Conference is "New Quality Productivity and Investment Opportunities in China," focusing on the open and innovative Shenzhen market [1] - The keynote speech by the founding partner of Qiming Venture Partners highlighted the significant transformation in China's export categories over the past 20 years, with machinery, electrical equipment, and consumer electronics now accounting for 42% of total exports [2][9] - The rapid growth of China's new energy electric vehicles demonstrates strong global competitiveness, with various companies expanding their international presence [2][10] Group 2 - The emergence of DeepSeek as a leading AI company signifies China's capability in AI, with its models showing performance comparable to OpenAI's at a fraction of the cost, indicating a shift in global perceptions of Chinese AI capabilities [5][6][7] - The biopharmaceutical sector in China is also experiencing rapid advancements, with 30% of global big pharma's license-in deals coming from Chinese biotech startups in 2024, up from 0% in 2019 [8][9] - The internationalization of Chinese tech companies is increasing, with notable examples like BYD and Xiaomi showing significant growth in overseas revenue [9][10] Group 3 - The venture capital industry in China plays a crucial role in supporting technological innovation, with a focus on high-risk tolerance and long-term value [12] - Despite facing challenges in recent years, the Chinese venture capital sector has produced a significant number of companies with valuations exceeding $100 billion, with six out of seven such companies globally founded after 2010 being Chinese [13] - Key investment opportunities are identified in sectors such as artificial intelligence, biomedicine, and renewable energy, with expectations for substantial growth and innovation in these areas [14]